Literature DB >> 15366645

A case of severe chronic active Epstein-Barr virus infection with T-cell lymphoproliferative disorder.

Hyun Seok Cho1, In Soon Kim, Hwan Cheol Park, Myung Ju Ahn, Young Yiul Lee, Chan Kum Park.   

Abstract

Chronic infection with Epstein-Barr virus (EBV) without previous immunodeficiency or immuno-suppressive therapy is relatively rare. Severe chronic active EBV (SCAEBV) infection was reported for the first time in 1984 as 'chronic mononucleosis syndrome', and diagnostic criteria were proposed. It is characterized by clinical features including fever, severe hepatosplenomegaly, lymphadenopathy, hematologic features such as anemia and thrombocytopenia, and elevated antibody titers to EBV. We experienced a 21-year-old woman who initially presented with fever and chronic fatigue; however, no definite diagnosis could be made at the time of admission. Three months after the initial admission, there was evidence of only splenomegaly and the patient had persistent, multiple, paraaortic lymphadenopathies in abdominal CT. Diagnostic splenectomy was performed, and SCAEBV infection with T-cell lymphoproliferative disorder was ultimately diagnosed.

Entities:  

Mesh:

Year:  2004        PMID: 15366645      PMCID: PMC4531591          DOI: 10.3904/kjim.2004.19.2.124

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  19 in total

1.  Clinical evaluation of patients with infectious mononucleosis and development of antibodies to the R component of the Epstein-Barr virus-induced early antigen complex.

Authors:  C A Horwitz; W Henle; G Henle; H Schmitz
Journal:  Am J Med       Date:  1975-03       Impact factor: 4.965

2.  Chronic infectious mononucleosis.

Authors:  R ISAACS
Journal:  Blood       Date:  1948-08       Impact factor: 22.113

Review 3.  The chronic mononucleosis syndrome.

Authors:  S E Straus
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

4.  Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2.

Authors:  K Kawa-Ha; E Franco; S Doi; K Yumura; S Ishihara; A Tawa; H Yabuuchi
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

5.  Vidarabine therapy for severe chronic active Epstein-Barr virus infection.

Authors:  H Kimura; M Morita; I Tsuge; Y Hoshino; N Tanaka; Y Ito; T Morishima
Journal:  J Pediatr Hematol Oncol       Date:  2001 Jun-Jul       Impact factor: 1.289

6.  Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy.

Authors:  R T Schooley; R W Carey; G Miller; W Henle; R Eastman; E J Mark; K Kenyon; E O Wheeler; R H Rubin
Journal:  Ann Intern Med       Date:  1986-05       Impact factor: 25.391

7.  Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation.

Authors:  T Okamura; Y Hatsukawa; H Arai; M Inoue; K Kawa
Journal:  Lancet       Date:  2000-07-15       Impact factor: 79.321

8.  Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

Authors:  A Fischer; S Blanche; J Le Bidois; P Bordigoni; J L Garnier; P Niaudet; F Morinet; F Le Deist; A M Fischer; C Griscelli
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

9.  Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society.

Authors:  S Imashuku; S Hibi; T Ohara; A Iwai; M Sako; M Kato; H Arakawa; M Sotomatsu; S Kataoka; K Asami; D Hasegawa; Y Kosaka; K Sano; N Igarashi; K Maruhashi; R Ichimi; H Kawasaki; N Maeda; A Tanizawa; K Arai; T Abe; H Hisakawa; H Miyashita; J I Henter
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

10.  T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections.

Authors:  J F Jones; S Shurin; C Abramowsky; R R Tubbs; C G Sciotto; R Wahl; J Sands; D Gottman; B Z Katz; J Sklar
Journal:  N Engl J Med       Date:  1988-03-24       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.